Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07472322 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1

StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date pushed from Sep 2026 to Oct 2026
    • Eligibility criteria expanded, about 11 words
    • Secondary endpoints: details revised at 3 of 6 entries
    • Site contact updated
  2. Start date: Aug 2026 to Sep 2026
    • Site contact updated
    v7
  3. Start date: Jul 2026 to Aug 2026
    • Site contact updated
    v6
  4. Start date: Jun 2026 to Jul 2026
    • Site contact updated
    v5
  5. Start date: May 2026 to Jun 2026
    • Site contact updated
    v4
  6. Site contact updatedv3
  7. Primary and study completion pushed from Apr 2031 to May 2031
    • Start date: Apr 2026 to May 2026
    v2
  8. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to learn if ASTX727 can be combined with retifanlimab to treat Merkel cell cancer. It will also learn about the safety of combining these drugs. The main questions it aims to answer are: * Can the combination shrink cancer and lower the chance of the cancer growing or spreading? * Is the combination better than standard of care for Merkel cell cancer? Participants will: * Take oral ASTX727 and retifanlimab through a vein in the arm for about 2 years. * Visit the clinic once every 2 weeks for checkups and tests
Trial Details
NCT Number NCT07472322
Lead Sponsor University of Wisconsin, Madison
Conditions
(from sponsor)		 Merkel Cell Carcinoma, Merkel Cell Carcinoma, Stage III, Merkel Cell Carcinoma, Stage IV
Related terms Carcinoma, Merkel Cell
Enrollment 31 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov